CardiaTec raises $6.5M for AI-driven drug discovery in cardiovascular diseases.
Cambridge University's CardiaTec has secured $6.5 million to advance AI-driven drug discovery for cardiovascular diseases (CVDs), which cause 17.9 million deaths annually. The startup is creating the largest human heart tissue multi-omics dataset through partnerships with 65 hospitals in the UK and US. By analyzing complex biological data, CardiaTec aims to uncover novel treatments and enhance understanding of CVD mechanisms.
6 months ago
4 Articles
Articles
Further Reading
Only 2 free stories left this month. Don’t miss out — Subscribe for unlimited access!